Positive news for Alumis Inc. as ESK-001 Phase 2 data shows sustained clinical responses in patients

From GlobeNewswire: 2025-03-08 09:00:00

Alumis Inc. announced positive 52-week data for ESK-001, a next-generation oral TYK2 inhibitor, showing sustained clinical responses in patients with moderate-to-severe plaque psoriasis. Results from the Phase 2 OLE trial demonstrated improvements in PASI 90, PASI 100, and sPGA 0, with no new safety concerns after one year of treatment. These findings support ESK-001 as a potential best-in-class treatment option. The Phase 3 ONWARD program is ongoing, with topline data expected in Q1 2026. ESK-001 aims to correct immune dysregulation in diseases like psoriasis by targeting proinflammatory mediators. Alumis is dedicated to improving patient outcomes with precision therapies.



Read more at GlobeNewswire: Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025